| P50 | author | Crandall Peeler | Q57085610 |
| | Zegabriel Tedla | Q57890252 |
| P2093 | author name string | Andrew Vernon | |
| | Charles D Wells | |
| | Taraz Samandari | |
| | Tefera Agizew | |
| | Oaitse Motsamai | |
| | Samba Nyirenda | |
| | Thabisa Sibanda | |
| P2860 | cites work | The growing burden of tuberculosis: global trends and interactions with the HIV epidemic | Q29616520 |
| | A population-based study on alcohol and high-risk sexual behaviors in Botswana | Q33259963 |
| | Isoniazid toxicity in health care workers. | Q33926290 |
| | Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study | Q34011661 |
| | Viral hepatitis in HIV infection | Q34086980 |
| | Severe acetaminophen toxicity in a patient receiving isoniazid | Q34260561 |
| | The toxicity of Callilepis laureola, a South African traditional herbal medicine | Q34283833 |
| | Drug-related hepatotoxicity | Q34495071 |
| | An official ATS statement: hepatotoxicity of antituberculosis therapy | Q34571651 |
| | The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil | Q34717877 |
| | Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort | Q34717889 |
| | Screening for problem drinking: comparison of CAGE and AUDIT. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test | Q34751960 |
| | Isoniazid-associated hepatitis deaths: a review of available information | Q36762694 |
| | The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies | Q37020081 |
| | Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse | Q37031150 |
| | Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary | Q37053004 |
| | Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy | Q38886539 |
| | A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration | Q38887663 |
| | Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. | Q39058099 |
| | Serological evidence of HIV-associated infection among HIV-1-infected adults in Botswana | Q39588236 |
| | Reactogenicity and immunogenicity of combined vaccines for bacteraemic diseases caused by Haemophilus influenzae type b, meningococci and pneumococci in 24-month-old children | Q40763717 |
| | Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana | Q40798969 |
| | HIV risk factors among patients with tuberculosis--Botswana 1999. | Q40801391 |
| | Twenty isoniazid-associated deaths in one state | Q42199228 |
| | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He | Q42622399 |
| | Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States | Q43996290 |
| | Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. | Q44260228 |
| | Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic | Q44440459 |
| | HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms | Q44778134 |
| | Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria | Q45471160 |
| | A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. | Q45761546 |
| | Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients | Q46293474 |
| | Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy | Q46430597 |
| | HIV, hepatitis B and hepatitis C coinfection in Kenya | Q46558487 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Botswana | Q963 |
| | isoniazid | Q423169 |
| | tuberculosis | Q12204 |
| | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 278-285 | |
| P577 | publication date | 2010-04-08 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana | |
| P478 | volume | 182 | |